Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Results for PRO 140 inspire IND filing
October 2018
SHARING OPTIONS:

VANCOUVER, Wash.—Biotechnology company CytoDyn Inc. recently announced that PRO 140 has demonstrated its effectiveness at inhibiting the growth of a human colon carcinoma cell line in a mouse model. CytoDyn used two strains of immunoincompetent mice to grow SW480 human tumor cells for its preclinical studies, a cell line that is derived from a colon adenocarcinoma patient and is CCR5-positive. The company reported that PRO 140 extended the lives of treated mice and decreased tumor growth by more than 50 percent compared to control mice. The results were dose-dependent, as noted in a press release, and repeated in separate experiments. CytoDyn has other preclinical studies underway to determine the mechanisms of PRO 14-'s anti-tumor efficacy. Based on the statistically significant data resulting from its preclinical work, the company plans to file an Investigative New Drug application with the FDA for a clinical trial in colon carcinoma patients.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.